［1］Su S,Lv JQ,Li N,et al.the clinical effect of pemetrexed and gemcitabine combined cisplatin the first-line treatment of advanced lung adenocarcinoma［J］.J Pract Med,2011,27(8):1458.［苏珊,吕江青,李宁,等.培美曲塞与吉西他滨联合铂类一线治疗晚期肺腺癌的临床疗效观察［J］.实用医学杂志,2011,27(8):1458.］
［2］Scagliotti G,Hanna N,Fossella F,et al.The differential efficacy of pemetrexed according to NSCLC histology:a review of two phase Ⅲ studies［J］.Oncologist,2009,14(3):253-263.
［3］Wang QZ,Luo Y,Zhu YH,et al.The clinical study of pemetrexed disodium combined cisplatin first-line treatment of advanced non-small cell lung cancer［J］.China and Rehabilitation of Clin Oncol,2010,17(6):513-515.［王倩之,罗以,朱跃红,等.培美曲塞二钠联合顺铂的一线治疗晚期非小细胞肺癌的临床研究［J］.中国肿瘤临床与康复,2010,17(6):513-515.］
［4］Shi MY,Chen YJ,Huang JA.Effect of exogenous folic acid pretreatment on killing of human lung adenocarcinoma A549 cells in vitro ［J］.Jiangsu Med J,2011,37(6):621-623.［施敏骅,陈永井,黄建安.外源性叶酸预处理影响培美曲塞对人肺腺癌A549细胞的体外杀伤作用［J］.江苏医药,2011,37(6):621-623.］
［5］Gao S,Wu R.Pemetrexed research progress for the treatment of malignant pleural mesothelioma ［J］.Pract Med Clin,2009,12(5):353-356.［高嵩,吴荣.培美曲塞治疗恶性胸膜间皮瘤的研究进展［J］.实用药物与临床,2009,12(5):353-356.］
［6］Yang BS,Chen KB,Shi WJ,et al.Clinical effect of pemetrexed gemcitabine respectively with cisplatin treatment of postoperative patients with lung adenocarcinoma［J］.Modern Oncolgy,2014,22(4):837-839.［杨保参,陈宽冰,石文君,等．培美曲塞/吉西他滨分别联合顺铂对肺腺癌术后化疗的临床疗效观察［J］.现代肿瘤医学,2014,22(4):837-839.］
［7］Wang YL.rhG-CSF the curative effect of prevention and treatment of advanced lung cancer after chemotherapy leucopenia ［J］.Pract Med Clin,2010,13(1):71-72.［王烨粦.rhG-CSF防治晚期肺癌化疗后白细胞减少的疗效［J］.实用药物与临床,2010,13(1):71-72.］
［8］Li WP,Liu H,Chen L,et al.A clinical comparision of lobaplatin or cisplatin with mitomycine and vincristine in treating patients with cervical squamous carcinoma［J］.Asian Pac J Cancer Prev,2015,16(11):4629-4631.
［9］Li JR,Sun Y,Liu L,et al.Radioactive seed implantation and lobaplatin chemotherapy are safe and effective in treating patients with advanced lung cancer［J］.Asian Pac J Cancer Prev,2015,16(9):4003-4006.
［10］Wang Q,Chan L.Clinical observation of docetaxel combined with cisplatin and dedaplain chemotherapy in the treatment of advanced non-small cell lung cancer［J］.J Xinjiang Med Univ,2009,32(7):3901-3905.［王强,单利.多西紫杉醇联合顺铂与联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床观察［J］.新疆医科大学学报,2009,32(7):3901-3905.］
［11］Zhang P,Feng FY,Wu LY,et al.Clinical study of nedaplatin in the treatment of malignant tumor［J］.Chin J Oncol,2006,3(28):230-234.［张频,冯奉仪,吴令英,等.奈达铂治疗恶性肿瘤的临床研究［J］.中华肿瘤杂志,2006,3(28):230-234.］
［12］Zhang S,Xu P,Yuan C,et al.Safety of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with IIIa lung adenocarcinoma［J］.Lung Cancer J China,2015,18(6):365-368.
［13］Buti S,Bordi P,Tiseo M,et al.Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients ［J］.Lung Cancer,2015,88(3):319-324.
［14］Zhou CZ,Qin YY,Xie ZH,et al.Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma ［J］.Chin J Cancer Res,2014,26(6):705-710.
［15］Rodrigues-Pereira J,Kim JH,Magallanes M,et al.A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced,nonsquamous nonsmall cell lung cancer［J］.J Thorac Oncol,2011,6(11):1907-1914.
［16］Klein R.Cost-effectiveness of pemetrexed plus cisplatin as firstline therapy for advanced nonsquamous non-small cell lung cancer［J］.J Thorac Oncol,2009,4(11):1404-1414.
［17］Chen JG,Yang XN,Guo AL,et al.Establishment of a diagnosis model for adenocarcinoma of the lung by using SELDI-TOF-MS protein fingerprinting technique［J］.J Pract Med,2010,26(7):1093-1096.［陈剑光,杨学宁,郭爱林,等．利用SELDI-TOF-MS 蛋白质指纹图谱技术建立肺腺癌诊断模型［J］.实用医学杂志,2010,26(7):1093-1096.］
［18］Deng QQ,Huang XE,Ye LH,et al.Phase II trial of Loubo (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes ［J］.Asian Pac J Cancer Pre,2013,14(1):413-417.
［19］Wu XY,Huang XE,Cao J,et al.A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer［J］.Asian Pac J Cancer Prev,2014,15(14):5941-5944.